Skip to main content

Table 3 Results of cost-effectiveness analysis

From: Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial

Group

E (QALY)

IE (QALY)

C (JPY 1000)

IC (JPY 1000)

S-1

2.11

0.070

5307

[USD 47,000]

−424

[USD 3750]

Taxane

2.04

 

5731

[USD 50,700]

 
  1. E Effectiveness, IE Incremental effectiveness, C Cost, IC Incremental cost
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us